Structure and Sequence Determinants Governing the Interactions of RNAs with Influenza A Virus Non-Structural Protein NS1.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
27 08 2020
Historique:
received: 13 07 2020
revised: 17 08 2020
accepted: 25 08 2020
entrez: 2 9 2020
pubmed: 2 9 2020
medline: 24 2 2021
Statut: epublish

Résumé

The non-structural protein NS1 of influenza A viruses is an RNA-binding protein of which its activities in the infected cell contribute to the success of the viral cycle, notably through interferon antagonism. We have previously shown that NS1 strongly binds RNA aptamers harbouring virus-specific sequence motifs (Marc et al., Nucleic Acids Res. 41, 434-449). Here, we started out investigating the putative role of one particular virus-specific motif through the phenotypic characterization of mutant viruses that were genetically engineered from the parental strain WSN. Unexpectedly, our data did not evidence biological importance of the putative binding of NS1 to this specific motif (UGAUUGAAG) in the 3'-untranslated region of its own mRNA. Next, we sought to identify specificity determinants in the NS1-RNA interaction through interaction assays in vitro with several RNA ligands and through solving by X-ray diffraction the 3D structure of several complexes associating NS1's RBD with RNAs of various affinities. Our data show that the RBD binds the GUAAC motif within double-stranded RNA helices with an apparent specificity that may rely on the sequence-encoded ability of the RNA to bend its axis. On the other hand, we showed that the RBD binds to the virus-specific AGCAAAAG motif when it is exposed in the apical loop of a high-affinity RNA aptamer, probably through a distinct mode of interaction that still requires structural characterization. Our data are consistent with more than one mode of interaction of NS1's RBD with RNAs, recognizing both structure and sequence determinants.

Identifiants

pubmed: 32867106
pii: v12090947
doi: 10.3390/v12090947
pmc: PMC7552008
pii:
doi:

Substances chimiques

3' Untranslated Regions 0
Aptamers, Nucleotide 0
INS1 protein, influenza virus 0
RNA, Double-Stranded 0
RNA, Messenger 0
RNA, Viral 0
RNA-Binding Proteins 0
Viral Nonstructural Proteins 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2011 May;85(10):5228-31
pubmed: 21411538
PLoS Pathog. 2013;9(7):e1003440
pubmed: 23853584
Nat Protoc. 2008;3(7):1213-27
pubmed: 18600227
J Mol Biol. 2017 Oct 27;429(21):3334-3352
pubmed: 28433538
Cell. 2009 Dec 24;139(7):1255-67
pubmed: 20064372
Curr Top Microbiol Immunol. 2015;386:73-107
pubmed: 25007846
Open Forum Infect Dis. 2017 May 18;4(3):ofx105
pubmed: 28852674
J Virol. 2013 May;87(10):5602-20
pubmed: 23468495
J Virol. 1999 Nov;73(11):9679-82
pubmed: 10516084
Nucleic Acids Res. 2013 Jan 7;41(1):434-49
pubmed: 23093596
J Virol. 2000 Sep;74(17):7989-96
pubmed: 10933707
Nucleic Acids Res. 1997 Nov 1;25(21):4271-7
pubmed: 9336457
Viruses. 2020 May 14;12(5):
pubmed: 32422922
Nucleic Acids Res. 1993 Dec 11;21(24):5670-8
pubmed: 8284214
Antiviral Res. 2013 Sep;99(3):409-16
pubmed: 23796981
J Virol. 2018 Nov 27;92(24):
pubmed: 30258002
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Gen Virol. 2008 Oct;89(Pt 10):2359-2376
pubmed: 18796704
Methods Mol Biol. 2008;488:99-115
pubmed: 18982286
Mol Cell. 2020 Apr 2;78(1):9-29
pubmed: 32243832
Cell Host Microbe. 2014 Dec 10;16(6):795-805
pubmed: 25464832
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Genes Dev. 1994 Aug 1;8(15):1817-28
pubmed: 7958859
EMBO J. 2003 Sep 15;22(18):4646-55
pubmed: 12970177
J Virol. 1994 Apr;68(4):2425-32
pubmed: 7908060
Nature. 2008 Dec 18;456(7224):985-8
pubmed: 18987632
Elife. 2015 Jan 02;4:
pubmed: 25555158
Front Plant Sci. 2018 Feb 01;9:70
pubmed: 29449856
Nucleic Acids Res. 2013 Dec;41(22):10476-87
pubmed: 24013566
Nat Microbiol. 2019 Oct;4(10):1671-1679
pubmed: 31263181
Biochemistry. 2009 Nov 3;48(43):10473-82
pubmed: 19795889
Curr Opin Virol. 2019 Apr;35:14-18
pubmed: 30852344
J Gen Virol. 1997 May;78 ( Pt 5):1059-63
pubmed: 9152423
J Virol. 1995 Apr;69(4):2427-33
pubmed: 7884890
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W68-73
pubmed: 21558323
EMBO Rep. 2005 Jan;6(1):33-8
pubmed: 15643449
Virol J. 2006 Aug 31;3:63
pubmed: 16945126
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1853-8
pubmed: 17267598
Infect Drug Resist. 2017 Apr 20;10:121-134
pubmed: 28458567
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
J Virol. 2015 Jun;89(12):6376-90
pubmed: 25855727
J Gen Virol. 2014 Dec;95(Pt 12):2594-2611
pubmed: 25182164
Cell Mol Life Sci. 2013 Jun;70(11):1875-95
pubmed: 22918483
Nucleic Acids Res. 2020 Jan 10;48(1):304-315
pubmed: 31754723
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):32-41
pubmed: 17164524
J Biol Chem. 2007 Jul 13;282(28):20584-92
pubmed: 17475623
Cell Microbiol. 2016 Jun;18(6):784-91
pubmed: 26687707
J Virol. 2014 Apr;88(8):4113-22
pubmed: 24478439
J Virol. 2012 Oct;86(19):10370-6
pubmed: 22787231
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
J Gen Virol. 2014 Oct;95(Pt 10):2099-2105
pubmed: 24928909
J Gen Virol. 1997 Oct;78 ( Pt 10):2447-51
pubmed: 9349463
GMS Infect Dis. 2017 Apr 25;5:Doc04
pubmed: 30671326
PLoS Pathog. 2012;8(11):e1002993
pubmed: 23144613
PLoS Pathog. 2014 Oct 02;10(10):e1004420
pubmed: 25275541
Cell Res. 2009 Feb;19(2):187-95
pubmed: 18813227
Nucleic Acids Res. 1999 Feb 1;27(3):882-7
pubmed: 9889287
J Virol. 2007 Sep;81(17):9469-80
pubmed: 17596305
Protein Expr Purif. 2005 May;41(1):207-34
pubmed: 15915565
Virol J. 2018 Mar 27;15(1):55
pubmed: 29587792

Auteurs

Alan Wacquiez (A)

Equipe 3IMo, UMR1282 Infectiologie et Santé Publique, INRAE, F-37380 Nouzilly, France.
UMR1282 Infectiologie et Santé Publique, Université de Tours, F-37000 Tours, France.
Centre de Biophysique Moléculaire, UPR4301 CNRS, rue Charles Sadron, CEDEX 02, 45071 Orléans, France.

Franck Coste (F)

Centre de Biophysique Moléculaire, UPR4301 CNRS, rue Charles Sadron, CEDEX 02, 45071 Orléans, France.

Emmanuel Kut (E)

Equipe 3IMo, UMR1282 Infectiologie et Santé Publique, INRAE, F-37380 Nouzilly, France.
UMR1282 Infectiologie et Santé Publique, Université de Tours, F-37000 Tours, France.

Virginie Gaudon (V)

Centre de Biophysique Moléculaire, UPR4301 CNRS, rue Charles Sadron, CEDEX 02, 45071 Orléans, France.

Sascha Trapp (S)

Equipe 3IMo, UMR1282 Infectiologie et Santé Publique, INRAE, F-37380 Nouzilly, France.
UMR1282 Infectiologie et Santé Publique, Université de Tours, F-37000 Tours, France.

Bertrand Castaing (B)

Centre de Biophysique Moléculaire, UPR4301 CNRS, rue Charles Sadron, CEDEX 02, 45071 Orléans, France.

Daniel Marc (D)

Equipe 3IMo, UMR1282 Infectiologie et Santé Publique, INRAE, F-37380 Nouzilly, France.
UMR1282 Infectiologie et Santé Publique, Université de Tours, F-37000 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH